Feedback / Questions
BRL03 - Biosyngen
https://www.prnewswire.com/news-releases/biosyngen-received-fda-approval-for-phase-iii-clinical-trials-for-brl03-targeting-lung-cancer-gastric-cancer-and-other-advanced-solid-tumors-301923030.html
Sep 11, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next